1-(6-Azaspiro[2.5]octan-6-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(6-Azaspiro[2.5]octan-6-yl)ethanone
• 英文别名: 1-(6-azaspiro[2.5]octan-6-yl)ethanone
• 化学式: C₉H₁₅NO
• 分子量: 153.22
• InChiKey: PDFBSBFILQFMFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE ET D'AUTRES MALADIES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2014002105A1

  公开（公告）日：2014-01-03

  The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as hyperlipidemia and also have a beneficial effect on cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐，含有它们的药物组合物，它们的制备方法，这些化合物在医学上的应用以及其制备中涉及的中间体。本发明针对可用于治疗高脂血症等疾病并对胆固醇产生有益影响的化合物。
• CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]
  申请人：Phenex Pharmaceuticals AG

  公开号：US20150175562A1

  公开（公告）日：2015-06-25

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了用于孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导的疾病的人类或哺乳动物注射这些新型RORy调节剂的方法。具体而言，本发明提供了公式（1）、（1'）、（100）、（100'）、（200）和（200'）的含有羧酰胺或磺酰胺的环状化合物及其对映异构体、互异构体、互变异构体、/V-氧化物、溶剂化物和药学上可接受的盐。
• COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES
  申请人：Cadila Healthcare Limited

  公开号：EP2864309A1

  公开（公告）日：2015-04-29
• SEPIAPTERIN REDUCTASE INHIBITORS
  申请人：QUARTET MEDICINE, INC.

  公开号：US20170096435A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
• USRE47493E1
  申请人：——

  公开号：USRE47493E1

  公开（公告）日：2019-07-09